Intuitive Surgical (ISRG) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with ISRG
Recent news

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
ISRG

3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
ISRG

2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade
2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade
ISRG

Can ISRG Offset China Weakness With Expansion in India and Japan?
Can ISRG Offset China Weakness With Expansion in India and Japan?
ISRG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 66.74
- MACD 12/26/9
- 9.45
- EMA 9 of MACD
- 7.83
- MACD histogram
- 1.62
- SMA 50
- $386.10
- Price above SMA 50
- EMA 50
- $393.08
- Price above EMA 50
- SMA 200
- $443.41
- Price below SMA 200
- EMA 200
- $445.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 19 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.03 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
ISRG

3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
ISRG

2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade
2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade
ISRG

Can ISRG Offset China Weakness With Expansion in India and Japan?
Can ISRG Offset China Weakness With Expansion in India and Japan?
ISRG

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
ISRG

Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.
Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.
ISRG

Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock
Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock
ISRG

Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
ISRG

Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
ISRG

Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
ISRG
News tone: automated (AI) classification of the article's content, not a price prediction.
About Intuitive Surgical
Intuitive was founded in 1995 to create innovative, robotic-assisted systems that help empower doctors and hospitals to make surgery less invasive than an open approach. Since the da Vinci surgical system became one of the first robotic-assisted systems cleared by the FDA for general laparoscopic surgery, we’ve taken robotic-assisted surgery from “science fiction” to reality. Working with doctors and hospitals, we’re continuing to develop new, minimally invasive surgical platforms and future diagnostic tools to help solve complex healthcare challenges around the world.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gary S. Guthart Ph.D. | Executive Chair | 1966 |
| Mr. David J. Rosa | CEO & Director | 1968 |
| Mr. Jamie E. Samath | Executive VP, CFO & Enterprise Technology Leader | 1971 |
| Mr. Henry L. Charlton | Senior VP of Global Business Operations | 1970 |
| Mr. Gary H. Loeb J.D. | Executive VP and Chief Legal & Compliance Officer | 1970 |
| Mr. Mark P. Brosius | Chief Manufacturing and Supply Chain Officer | 1967 |
| Mr. Fredrik Widman | VP, Principal Accounting Officer & Corporate Controller | — |
| Mr. Milind Wagle | Chief Information Officer | — |
| Mr. Daniel P. Connally C.F.A. | VP & Head of Investor Relations | — |
| Dr. Christopher R. Carlson Ph.D. | Executive Vice President of Research, Corporate Development, Corporate Strategy & Intuitive Ventures | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 66.74
- MACD 12/26/9
- 9.45
- EMA 9 of MACD
- 7.83
- MACD histogram
- 1.62
- SMA 50
- $386.10
- Price above SMA 50
- EMA 50
- $393.08
- Price above EMA 50
- SMA 200
- $443.41
- Price below SMA 200
- EMA 200
- $445.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
19 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $375.00
- Average
- $516.26
- High
- $931.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +10.8 | -8.6 | +12.3 | |||||||||
| 2022 | -21.1 | +1.3 | +3.5 | -21.7 | -5.4 | -7.2 | +11.7 | -10.0 | -9.1 | +27.5 | +9.5 | -3.3 |
| 2023 | -7.5 | -8.7 | +12.4 | +18.8 | +1.6 | +10.1 | -3.5 | -3.5 | -5.8 | -11.1 | +14.9 | +7.0 |
| 2024 | +14.3 | +0.5 | +0.3 | -6.1 | +8.2 | +10.1 | +1.9 | +9.2 | +1.6 | +3.9 | +7.0 | -3.8 |
| 2025 | +9.1 | -0.9 | -12.6 | +3.9 | +6.8 | -1.8 | -10.6 | -2.0 | -4.7 | +22.0 | +5.4 | -0.2 |
| 2026 | -10.3 | +1.4 | -7.1 | -1.5 | -7.2 | -3.5 | -12.2 | +0.4 | +10.1 | +5.7 |



